{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:10:44Z","timestamp":1790028644406,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.exer.2021.108489","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:12:22Z","timestamp":1613347942000},"page":"108489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Prostaglandin F2\u03b1 and EP2 agonists, and a ROCK inhibitor modulate the formation of 3D organoids of Grave's orbitopathy related human orbital fibroblasts"],"prefix":"10.1016","volume":"205","author":[{"given":"Hanae","family":"Ichioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5165-6507","authenticated-orcid":false,"given":"Yosuke","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ohguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihito","family":"Hikage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2021.108489_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajo.2020.06.003","article-title":"Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: ThePhase 3 AYAME study","volume":"220","author":"Aihara","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108489_bib2","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","article-title":"Side effects associated with prostaglandin analog therapy","volume":"53 Suppl1","author":"Alm","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108489_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2021.108489_bib4","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1167\/iovs.18-25134","article-title":"The effect of prostaglandin analogue bimatoprost on thyroid-associated orbitopathy","volume":"59","author":"Choi","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108489_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/jop.2011.0160","article-title":"In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes","volume":"28","author":"Choi","year":"2012","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2021.108489_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4161\/adip.19752","article-title":"Peri-adipocyte ECM remodeling in obesity and adipose tissue fibrosis","volume":"1","author":"Chun","year":"2012","journal-title":"Adipocyte"},{"key":"10.1016\/j.exer.2021.108489_bib7","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/s41598-018-20821-3","article-title":"Anti-adipogenic effects of KD025 (SLx-2119), a ROCK2-specific inhibitor, in 3T3-L1 cells","volume":"8","author":"Diep","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exer.2021.108489_bib8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1089\/thy.2013.0194","article-title":"Effects of prostaglandin F(2\u03b1) on adipocyte biology relevant to graves' orbitopathy","volume":"23","author":"Draman","year":"2013","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"key":"10.1016\/j.exer.2021.108489_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/thy.2018.0506","article-title":"Prostaglandin F2-alpha eye drops (bimatoprost) in graves' orbitopathy: a randomized controlled double-masked crossover trial (BIMA trial)","volume":"29","author":"Draman","year":"2019","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"key":"10.1016\/j.exer.2021.108489_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1046\/j.1471-4159.1997.68020704.x","article-title":"Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells","volume":"68","author":"Fiebich","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.exer.2021.108489_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/jop.2017.0146","article-title":"Effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys","volume":"34","author":"Fuwa","year":"2018","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2021.108489_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1054\/plef.2001.0250","article-title":"Mechanisms involved in prostaglandin-induced increase in bone resorption in neonatal mouse calvaria","volume":"64","author":"Gardner","year":"2001","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.exer.2021.108489_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ajo.2006.02.047","article-title":"Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment","volume":"142","author":"Garrity","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108489_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/en.2018-00272","article-title":"HIF2A-LOX pathway promotes fibrotic tissue remodeling in thyroid-associated orbitopathy","volume":"160","author":"Hikage","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.exer.2021.108489_bib15","first-page":"1194","article-title":"Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy","volume":"85","author":"Hiromatsu","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.exer.2021.108489_bib16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.tcb.2011.09.005","article-title":"From 3D cell culture to organs-on-chips","volume":"21","author":"Huh","year":"2011","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.exer.2021.108489_bib17","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1038\/s41598-020-64674-1","article-title":"Prostaglandin F2\u03b1 agonist-induced suppression of 3T3-L1 cell adipogenesis affects spatial formation of extra-cellular matrix","volume":"10","author":"Ida","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exer.2021.108489_bib18","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/s41598-020-72538-x","article-title":"Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells","volume":"10","author":"Ida","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exer.2021.108489_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/iovs.61.6.13","article-title":"Prostaglandin F2\u03b1 agonists negatively modulate the size of 3D organoids from primary human orbital fibroblasts","volume":"61","author":"Itoh","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108489_bib20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/bjophthalmol-2017-310723","article-title":"Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy","volume":"102","author":"Jang","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108489_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/01676830.2010.527028","article-title":"Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues","volume":"29","author":"Jayaprakasam","year":"2010","journal-title":"Orbit"},{"key":"10.1016\/j.exer.2021.108489_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0300-595X(85)80037-2","article-title":"The pathogenesis of Graves' ophthalmopathy","volume":"14","author":"Kendall-Taylor","year":"1985","journal-title":"Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.exer.2021.108489_bib23","first-page":"6677","article-title":"Thyroid dysfunction: an autoimmune aspect","volume":"8","author":"Khan","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.exer.2021.108489_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1167\/iovs.17-22745","article-title":"Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent","volume":"59","author":"Kirihara","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108489_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1167\/iovs.10-5276","article-title":"Altered ganglioside expression modulates the pathogenic mechanism of thyroid-associated ophthalmopathy by increase in hyaluronic acid","volume":"52","author":"Kook","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108489_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ceo.12163","article-title":"Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost","volume":"42","author":"Kucukevcilioglu","year":"2014","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108489_bib27","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/thy.2015.0254","article-title":"Forkhead transcription factor FOXO1 is regulated by both a stimulatory thyrotropin receptor antibody and insulin-like growth factor-1 in orbital fibroblasts from patients with graves' ophthalmopathy","volume":"25","author":"Kumar","year":"2015","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"key":"10.1016\/j.exer.2021.108489_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2021.108489_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096249","article-title":"Cross-sectional study of the association between a deepening of the upper eyelid sulcus-like appearance and wide-open eyes","volume":"9","author":"Nakakura","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.exer.2021.108489_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0163-7827(93)90017-Q","article-title":"Prostanoid receptors and their biological actions","volume":"32","author":"Negishi","year":"1993","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.exer.2021.108489_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10384-010-0904-z","article-title":"Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost","volume":"55","author":"Park","year":"2011","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.exer.2021.108489_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061638","article-title":"A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features","volume":"8","author":"Shah","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.exer.2021.108489_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrendo.2014.226","article-title":"TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy","volume":"11","author":"Smith","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.exer.2021.108489_bib34","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2021.108489_bib35","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2021.108489_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/thy.1997.7.3","article-title":"TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema","volume":"7","author":"Stadlmayr","year":"1997","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"key":"10.1016\/j.exer.2021.108489_bib37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cmet.2013.06.016","article-title":"Fibrosis and adipose tissue dysfunction","volume":"18","author":"Sun","year":"2013","journal-title":"Cell Metabol."},{"key":"10.1016\/j.exer.2021.108489_bib38","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1167\/iovs.13-12589","article-title":"Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy","volume":"55","author":"Taketani","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108489_bib39","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1210\/jc.2013-1149","article-title":"A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy","volume":"98","author":"Turcu","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.exer.2021.108489_bib40","first-page":"87","article-title":"The interaction of hyaluronate with the cell surface: the hyaluronate receptor and the core protein","volume":"143","author":"Underhill","year":"1989","journal-title":"Ciba Foundation symposium"},{"key":"10.1016\/j.exer.2021.108489_bib41","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1167\/iovs.08-2443","article-title":"Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy","volume":"50","author":"van Steensel","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108489_bib42","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1167\/iovs.14-14002","article-title":"Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"55","author":"Wang","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108489_bib43","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves' disease","volume":"343","author":"Weetman","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2021.108489_bib44","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1167\/iovs.10-6867","article-title":"Characterization of ocular tissues using microindentation and hertzian viscoelastic models","volume":"52","author":"Yoo","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2021.108489_bib45","doi-asserted-by":"crossref","first-page":"26447","DOI":"10.1074\/jbc.M109.003616","article-title":"Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction","volume":"284","author":"Zhang","year":"2009","journal-title":"J. Biol. Chem."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483521000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483521000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:12:07Z","timestamp":1757999527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483521000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":45,"alternative-id":["S0014483521000543"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2021.108489","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostaglandin F2\u03b1 and EP2 agonists, and a ROCK inhibitor modulate the formation of 3D organoids of Grave's orbitopathy related human orbital fibroblasts","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2021.108489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108489"}}